Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.40 |
| ▸ | ITGAV | P06756 | 15/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.38 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716436 | 0.84 | CXCR4 (0.43) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL4717990 | 0.83 | CXCR4 (0.43) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL4716151 | 0.81 | ITGAV (0.44) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL14222590 | 0.81 | ITGAV (0.45) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL4719999 | 0.80 | ITGAV (0.42) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL4715246 | 0.80 | ITGAV (0.44) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL4716011 | 0.80 | ITGAV (0.45) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL4716440 | 0.79 | ITGAV (0.41) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL4714670 | 0.77 | ITGAV (0.45) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL4718079 | 0.76 | ITGAV (0.47) | ITGAVITGB3ITGB6ITGB5ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |